INS and diabetes mellitus: NPs are effective insulin carriers through the sublingual route and have been verified in streptozotocin-induced mouse models with diabetes by acquiring increased bioavailability of 24.1% and high pharmacological potential of 20.2%, as compared to the injection (1 IU/kg) administered through subcutaneous route [86].